AnaptysBio (NASDAQ:ANAB) Sets New 12-Month High at $41.11

AnaptysBio, Inc. (NASDAQ:ANAB) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $41.11 and last traded at $40.56, with a volume of 366230 shares changing hands. The stock had previously closed at $33.33.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ANAB. Wedbush restated an “outperform” rating and set a $34.00 price target on shares of AnaptysBio in a research report on Friday, May 10th. SVB Leerink began coverage on AnaptysBio in a research report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 target price for the company. Leerink Partnrs reissued an “outperform” rating on shares of AnaptysBio in a research report on Tuesday, April 16th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of AnaptysBio in a research note on Tuesday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus target price of $52.56.

AnaptysBio Trading Up 18.0 %

The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -6.63 and a beta of -0.25. The stock’s fifty day moving average price is $28.97 and its two-hundred day moving average price is $25.43.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. Analysts anticipate that AnaptysBio, Inc. will post -6.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the transaction, the insider now directly owns 11,618 shares in the company, valued at $406,630. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Dennis M. Fenton sold 1,950 shares of AnaptysBio stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $23.17, for a total transaction of $45,181.50. Following the sale, the director now owns 1,950 shares in the company, valued at $45,181.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the sale, the insider now directly owns 11,618 shares of the company’s stock, valued at $406,630. The disclosure for this sale can be found here. Insiders sold a total of 16,900 shares of company stock worth $484,824 over the last 90 days. 33.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ANAB. Allspring Global Investments Holdings LLC acquired a new stake in shares of AnaptysBio in the first quarter valued at approximately $38,000. Headlands Technologies LLC grew its position in AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in AnaptysBio by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 2,051 shares during the period. Quest Partners LLC purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $119,000. Finally, SG Americas Securities LLC purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $126,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.